The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...
Interesting Engineering on MSN8d
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback